Current status of circulating protein biomarkers to aid the early detection of lung cancer

Future Oncology

Volumn 10, Issue 8, 2014, Pages 1501-1513

  Hirales Casillas, Carlos Enrique ^a   Flores Fernández, José Miguel ^a   Camberos, Eduardo Padilla ^a   Herrera López, Enrique J ^a   Pacheco, Gisela Leal ^a   Velázquez, Moisés Martínez ^a  

^a CENTRO DE INVESTIGACIÓN Y ASISTENCIA EN TECNOLOGÍA Y DISEÑO DEL ESTADO DE JALISCO   (Mexico)

Author keywords

blood test; data analysis methods; early detection; high risk population; lung cancer; multiple biomarker panels; screening

Indexed keywords

BIOLOGICAL MARKER; DIAGNOSTIC KIT; PLASMA PROTEIN;

ARTIFICIAL INTELLIGENCE; CANCER MORTALITY; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC KIT; EARLY CANCER; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; HUMAN; LUNG CANCER; PRIORITY JOURNAL; REVIEW; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY; BLOOD; DIAGNOSTIC IMAGING; LUNG NEOPLASMS; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; BLOOD PROTEINS; DIAGNOSTIC IMAGING; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84905253378     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.21     Document Type: Review

References (68)

1. World Health Organization (WHO). The global burden of disease: 2004 Update. www.who.int/entity/healthinfo/global- burden-disease/GBD-report-2004update-full.pdf
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
3. Ezzati M, Henley SJ, Lopez AD, Thun MJ. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int. J. Cancer 116, 963-971 (2005)
4. U.S. Preventive Services Task Force. Lung cancer screening. Recommendation statement. www.uspreventiveservicestaskforce.org/3rduspstf/lungcancer/lungcanrs.htm#contents
5. Humphrey LL, Johnson M, Teutsch S. Lung cancer screening: an update for the US Preventive Services Task Force. www.ncbi.nlm.nih.gov/books/NBK42879
6. Spiro SG, Porter JC. Lung cancer-where are we today? Current advances in staging and nonsurgical treatment. Am. J. Respir. Crit. Care Med. 166, 1166-1196 (2002).
7. Ghosal R, Kloer P, Lewis KE. A review of novel biological tools used in screening for the early detection of lung cancer. Postgrad. Med. J. 85, 358-363 (2009).
8. Farlow EC, Patel K, Basu S et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin. Cancer Res. 16, 3452-3462 (2010).
9. Farlow EC, Vercillo MS, Coon JS et al. A multi-analyte serum test for the detection of non-small cell lung cancer. Br. J. Cancer 103, 1221-1228 (2010).
10. Rossi A, Maione P, Colantuoni G et al. Screening for lung cancer: new horizons? Crit. Rev. Oncol. Hemat. 56, 311-320 (2005).
11. Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR. Early detection and screening of lung cancer. Expert Rev. Mol. Diagn. 10, 799-815 (2010).
12. Hocking WG, Hu P, Oken MM et al. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. J. Natl Cancer Inst. 102, 722-731 (2010).
13. Oken M, Hocking WG, Kvale P et al. Screening by chest radiography and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 306, 1865-1873 (2011).
14. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 8, 142-150 (2011).
15. Fass L. Imaging and cancer. A review. Mol. Oncol. 2, 115-152 (2008).
16. International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF et al. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 355, 1763-1771 (2006).
17. National Lung Screening Trial Research TeamAberle DR, Adams AM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395-409 (2011).
18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. www.nccn.org/professionals/physician-gls/f- guidelines.asp
19. Nederlands-LeuvensLongkanker Screenings Onderzoek. Providing guidance on lung cancer screening to patients and physicians. www.lung.org/lung-disease/lung-cancer/lung-cancer-screening-guidelines/lung-cancer-screening.pdf
20. Larici A, Amato M, Ordóñez P et al. Detection of noncalcifed pulmonary nodules on low-dose MDCT: comparison of the sensitivity of two CAD systems by using a double reference standard. Radiol. Med. 117, 953-967 (2012).
21. Jaklitsch MT, Jacobson FL, Austin JH et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J. Thorac. Cardiovasc. Surg. 144, 33-38 (2012).
22. Ocak S, Chaurand P, Massion PP. Mass spectrometry-based proteomic profling of lung cancer. Proc. Am. Thorac. Soc. 6, 159-170 (2009).
23. Hassanein M, Rahman JS, Chaurand P, Massion PP. Advances in proteomic strategies toward the early detection of lung cancer. Proc. Am. Thorac. Soc. 8, 183-188 (2011).
24. Zeng X, Hood BL, Zhao T et al. Lung cancer serum biomarker discovery using label free LC-MS/MS. J. Thorac. Oncol. 6, 725-734 (2011).
25. Yildiz PB, Shyr Y, Rahman JS et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J. Thorac. Oncol. 2, 893-901 (2007).
26. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 5, 588-599 (2008).
27. Jakupciak JP, Maragh S, Markowitz ME et al. Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer 8, 285 (2008).
28. Ostrow KL, Hoque MO, Loyo M et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specifc PCR. Clin. Cancer Res. 16, 3463-3472 (2010).
29. Van't Westeinde SC, van Klaveren RJ. Screening and early detection of lung cancer. Cancer J. 17, 3-10 (2011).
30. Begum S, Brait M, Dasgupta S et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17, 4494-4503 (2011).
31. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997-1006 (2008).
32. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identifed in a genome-wide serum microRNA expression profling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28, 1721-1726 (2010).
33. Boeri M, Verri C, Conte D et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl Acad. Sci. USA 108, 3713-3718 (2011).
34. Bianchi F, Nicassio F, Marzi M et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol. Med. 3, 495-503 (2011).
35. Chen X, Hu Z, Wang W et al. Identifcation of ten serum microRNAs from a genome-wide serum microRNA expression profle as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int. J. Cancer 130, 1620-1628 (2012).
36. Hennessey P T, Sanford T, Choudhary A et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS ONE 7, e32307 (2012).
37. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profling tumor-associated antibodies for early detection of non-small cell lung cancer. J. Thorac. Oncol. 1, 513-519 (2006).
38. Khattar NH, Coe-Atkinson SP, Stromberg AJ, Jett JR, Hirschowitz EA. Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer. Cancer Biol. Ther. 10, 267-272 (2010).
39. Rom W, Goldberg JD, Addrizzo-Harris D et al. Identifcation of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer 10, 234 (2010).
40. Li XJ, Hayward C, Fong PY et al. A blood-based proteomic classifer for the molecular characterization of pulmonary nodules. Sci. Trans l. Med. 5, 207ra142 (2013).
41. Ostroff RM, Bigbee WL, Franklin W et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS ONE 5, e15003 (2010).
42. Schneider J, Bitterlich N, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor-marker profles improved sensitivity in the diagnosis of lung cancer. Int. J. Clin. Oncol. 7, 145-151 (2002).
43. Gao WM, Kuick R, Orchekowski R et al. Distinctive serum protein profles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 5, 110 (2005).
44. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE. Panel of serum biomarkers for the diagnosis of lung cancer. J. Clin. Oncol. 25, 5578-5583 (2007).
45. Schneider J, Bitterlich N, Kotschy-Lang N, Raab W, Woitowitz HJ. A fuzzy-classifer using a marker panel for the detection of lung cancers in asbestosis patients. Anticancer Res. 27, 1869-1877 (2007).
46. Borgia JA, Basu S, Faber LP et al. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J. Thorac. Oncol. 4, 338-347 (2009).
47. Leidinger P, Keller A, Heisel S et al. Identifcation of lung cancer with high sensitivity and specifcity by blood testing. Respir. Res. 11, 18 (2010).
48. Schneider J. Detection of lung cancer in silicosis patients using a tumor-marker panel. Cancer Biomark. 6, 137-148 (2010).
49. Boyle P, Chapman CJ, Holdenrieder S et al. Clinical validation of an autoantibody test for lung cancer. Ann. Oncol. 22, 383-389 (2011).
50. Lam S, Boyle P, Healey GF et al. Early CDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev. Res. 4, 1126-1134 (2011).
51. Wu Y, Wu Y, Wang J et al. An optimal tumor marker group-coupled artifcial neural network for diagnosis of lung cancer. Expert Syst. Appl. 38, 11329-11334 (2011).
52. Feng F, Wu Y, Wu Y, Nie G, Ni R. The effect of artifcial neural network model combined with six tumor markers in auxiliary diagnosis of lung cancer. J. Med. Syst. 36, 2973-2980 (2011).
53. Bigbee WL, Gopalakrishnan V, Weissfeld JL et al. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J. Thorac. Oncol. 7, 698-708 (2012).
54. Lee HJ, Kim YT, Park PJ et al. A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profling. J. Thorac. Cardiovasc. Surg. 143, 421-427 (2012).
55. Flores-Fernandez JM, Herrera-Lopez EJ, Sánchez-Llamas F et al. Development of an optimized multi-biomarker panel for the detection of lung cancer based on principal component analysis and artifcial neural network modeling. Expert Syst. Appl. 39, 10851-10856 (2012).
56. Chapman CJ, Healey GF, Murray A et al. EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biol. 33, 1319-1326 (2012).
57. Macdonald IK, Murray A, Healey GF et al. Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT®-Lung test. PLoS ONE 7, e51002 (2012).
58. Flores-Fernandez JM, Herrera E, Leal G et al. Artifcial neural network-based serum biomarkers analysis improves sensitivity in the diagnosis of lung cancer. In: IFMBE Proceedings of V Latin American Congress on Biomedical Engineering CLAIB 2011 (Volume 33). Folgueras MJ, Aznielle RTY, Calderón MCF et al. et al. (Eds). Springer, La Habana, Cuba, 882-885 (2013).
59. Daly S, Rinewalt D, Fhied C et al. Development and validation of a plasma biomarker panel for discerning clinical signifcance of indeterminate pulmonary nodules. J. Thorac. Oncol. 8, 31-36 (2013).
60. Rencher AC. Methods of Multivariate Analysis. Wiley Press, NY, USA (2002).
61. Richard's M, Sonalas A, Ledesma R, Introzzi I, López MF. [Classifcation statistical techniques: an applied and comparative study]. Psicothema 20, 863-871 (2008).
62. Breiman L. Random forests. Mach. Learn. 45, 5-32 (2001).
63. Woodcock J, Repoli A, Lebowits MS. The development, validation, and clinical utility of our multiplex biomarker panel for the early detection of lung cancer. http://genesysbiolabs.com/early-detection-of-lung-cancer-with-a-blood-test/for-physicians/paulas-test-facts
64. ®-Lung. www.oncimmune.com
65. ®-Lung. J. Thorac. Oncol. 7, S222 (2012).
66. Massion P, Peek LJ, Fredericks L, Jewell W, Pingleton W W, Robertson JFR. Autoantibodies to a panel of lung cancer-associated antigens can provide signifcant discrimination between malignant and non-malignant lung nodules. J. Thorac. Oncol. 8, S979 (2013)
67. Early Cancer Detection Test-Lung Cancer Scotland (ECLS Study). www.eclsstudy.org/home
68. Pepe MS, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054-1061 (2001).